Efficacy and Safety Study With Visonac Photodynamic Therapy (PDT) - Full Text View

Sponsored by:	PhotoCure
Information provided by:	PhotoCure
ClinicalTrials.gov Identifier:	NCT00933543

Purpose

The purpose of this trial is to study the efficacy and safety of Visonac PDT in patients from 9 to 35 years old with Aktilite® CL512.

Condition	Intervention	Phase
Acne Vulgaris	Drug: Visonac PDT (MAL PDT) Drug: Vehicle cream (placebo) Procedure: PDT	Phase II

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Parallel Assignment, Safety/Efficacy Study
Official Title:	A Double Blinded, Prospective, Randomized, Stratified, Placebo-Controlled, Multi-Center Study of Photodynamic Therapy With VisonacTM Cream in Patients With Moderate to Severe Acne Vulgaris.

Resource links provided by NLM:

MedlinePlus related topics: Acne

U.S. FDA Resources

Further study details as provided by PhotoCure:

Primary Outcome Measures:

Proportion of patients with success according to the dichotomized IGA scale based on facial assessments 12 weeks after the first treatment. Success is defined as an improvement of at least 2 grades from the baseline score. [ Time Frame: 12 weeks after the first treatment ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Proportion of patients with success according to the dichotomized IGA scale based on the facial (excluding lesions on nose) assessment at 12 weeks after the first treatment. [ Time Frame: 12 weeks after the first treatment ] [ Designated as safety issue: No ]

Estimated Enrollment:	100
Study Start Date:	August 2009
Estimated Study Completion Date:	April 2010
Estimated Primary Completion Date:	April 2010 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Visonac cream with PDT: Experimental Active treatment, Light dose 37 J/cm2.	Drug: Visonac PDT (MAL PDT) Cream application followed by illumination with red light. Procedure: PDT Photodynamic Therapy - Light dose 37 J/cm2
Vehicle cream with PDT: Placebo Comparator Placebo treatment, Light dose 37 J/cm2.	Drug: Vehicle cream (placebo) Cream application followed by illumination with red light. Procedure: PDT Photodynamic Therapy - Light dose 37 J/cm2

Detailed Description:

Double blinded, prospective, randomized, stratified, placebo-controlled, multi-center study in patients with moderate to severe acne vulgaris. Patients with facial severity grades 3 to 4 on the Investigator's Global Assessment (IGA) scale will be included. Each patient will be classified according to age in the two age groups 9 to 12 years and 13 to 35 years and randomized to either Visonac or vehicle cream within each age group. All patients will receive 4 treatments 2 weeks apart (at week 0, 2 ,4 and 6 week). Efficacy evaluation will be done after each treatment and at 12 weeks after the first treatment. Safety evaluations will be performed at each treatment visit and at 12 weeks after the first treatment. Photographs of patients will be taken before and after treatment at first and last treatment visit, and at 12 weeks after first treatment. Blood samples will be drawn at 3 visits; pre-treatment visit, one week after first treatment and at one week after last treatment visit.

Eligibility

Ages Eligible for Study:	9 Years to 35 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Female and male patients, above 9 years of age with moderate to severe facial acne vulgaris (IGA score 3-4).
Female patients who are surgically sterile, pre-menstrual, postmenopausal, abstinent, or willing to use an adequate means of contraception including birth control pills, or barrier methods and spermicide for at least 14 days prior to T1. Patients using birth control pills must have used the same product and dose for at least 6 months and must agree to stay with the same product and dose for an additional 6 months.
Fitzpatrick skin type I through VI.
Patients with 20 to 100 inflammatory lesions (papules, pustules, and nodules) on the face.
Patients with 30 to 120 non-inflammatory lesions (open and closed comedones) on the face.
Patients with no more than 2 nodular lesions on the face.
Signed and verified informed consent form. For subjects under age of 18, an assent form in conjunction with an informed consent form, signed and verified by parent/guardian.

Exclusion Criteria:

Patients presenting with any of the following will not be included in the study:

Patient is the investigator or any sub investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol.
Patients unlikely to comply with the protocol, e.g., mental condition rendering the patient unable to understand the nature, scope, and possible consequences of the clinical study, uncooperative attitude or unlikelihood of completing the study (e.g., drug or alcohol abuse).
Female patients using oral contraceptives, that have not used the same product or dose within the last 6 months and do not agree to stay with the same product and dose for the duration of the study.
Pregnancy
Patients undergoing testosterone or any other systemic hormonal treatment.
Patients using hormonal contraceptives solely for the control of acne.
Known allergy to MAL, to a similar PDT compound, or to excipients of the cream.
Patients with porphyria.
Patients with cutaneous photosensitivity.
Participation in other clinical studies either concurrently or within the last 30 days, before T1.
Patients with a washout period for topical treatments e.g., topical BPOs, retinoids and antibiotics, for their acne of less than 14 days, before T1. Medicated cleansers may be used during the washout period and stopped before the treatment.
Patients with a washout period for oral antibiotics for treatment of their acne of less than 1 month, before T1.
Patients with a washout period for oral isotretinoin of less than 6 months, before T1.
Patients with a beard or other facial hair that might interfere with study assessments.
Patients with melanoma or dysplastic nevi in the treatment area.
Exposure to ultraviolet radiation (UVB phototherapy, sun tanning salons) within the last 30 days.
Exposure to PDT within 12 weeks before T1.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00933543

Contacts

Contact: Saeeda Rana, MSc	+4722061646	sr@photocure.no
Contact: Per Fuglerud, MSc	+4722061654	pf@photocure.no

Locations

United States, California
Children's Specialists of San Diego / Rady Children's Hospital San Diego
San Diego, California, United States, 92123

Sponsors and Collaborators

PhotoCure

Investigators

Principal Investigator:

Lawrence F. Eichenfield, M.D

Children's Specialists of San Diego / Rady Children's Hospital San Diego

More Information

No publications provided

Responsible Party:	Photocure ( Saeeda Rana/ Clinical Trial Manager )
Study ID Numbers:	PC TA204/09
Study First Received:	July 2, 2009
Last Updated:	July 10, 2009
ClinicalTrials.gov Identifier:	NCT00933543 History of Changes
Health Authority:	United States: Food and Drug Administration

Keywords provided by PhotoCure:

Acne Vulgaris
Moderate to severe

Study placed in the following topic categories:

Exanthema
Facial Dermatoses
Facies

Skin Diseases
Sebaceous Gland Diseases
Acne Vulgaris

Additional relevant MeSH terms:

Facial Dermatoses
Skin Diseases
Acneiform Eruptions
Sebaceous Gland Diseases
Acne Vulgaris

ClinicalTrials.gov processed this record on September 10, 2009